Plus Therapeutics (PSTV) Total Current Liabilities (2010 - 2026)

Plus Therapeutics (PSTV) has 17 years of Total Current Liabilities data on file, last reported at $8.0 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $8.0 million, down 24.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.0 million (down 24.66% YoY), and the FY2025 annual result was $12.3 million, down 20.82% from the prior year.
• Total Current Liabilities retreated to $8.0 million in Q1 2026 per PSTV's latest filing, from $12.3 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $18.8 million in Q2 2024 and troughed at $4.9 million in Q1 2022.
• A 5-year average of $10.9 million and a median of $10.7 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Current Liabilities jumped 160.03% in 2023, then tumbled 61.06% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $11.9 million in 2022, then retreated by 9.49% to $10.7 million in 2023, then soared by 44.97% to $15.6 million in 2024, then retreated by 20.82% to $12.3 million in 2025, then slumped by 35.4% to $8.0 million in 2026.
• Business Quant data shows PSTV's Total Current Liabilities at $8.0 million in Q1 2026, $12.3 million in Q4 2025, and $13.6 million in Q3 2025.